Current Diagnostics and Therapy of Oligodendrogliomas

Czech version

Authors: J. Mraček ¹; M. Choc ¹; O. Hes ²; T. Vaněček ²
Authors‘ workplace: Neurochirurgické oddělení FN Plzeň ¹; Ústav patologické anatomie FN Plzeň ²
Published in: Cesk Slov Neurol N 2008; 71/104(5): 537-543
Category: Review Article

Overview

Oligodendrogli al tumo urs represent 15– 25% of all brain gli omas. They differ from other gli omas in having a better prognosis. Beca use no immunohistochemical marker has been fo und that can reli ably identify tumo urs of oligodendrocytes, histological findings are often misinterpreted and oligodendrogli omas are less frequently di agnosed in clinical practice. A large number of pati ents thus receive suboptimal care. Molecular cytogenetics has recently begun to play a major role in histological di agnosis and prognosticati on. Chemotherapy has an important role in contemporary management of oligodendrogli omas alongside surgery and radi otherapy. Tumo urs have a high response rate to the triple combinati on PCV (Procarbazine- Lomustine- Vincristine) or Temozolomide. The combined loss of chromosome arms 1p/ 19q is associ ated with a better prognosis. The pati ents with oligodendrogli omas in this study are presented from the commencement of cytogenetic investigati on. While better histological di agnosis has led to a rapid incre ase in oligodendrogli oma detecti on, the appro ach of some oncologists to its tre atment remain unchanged. Management of brain tumo urs in the present continues to demand an incre asingly multidisciplinary appro ach.

Key words:
oligodendroglioma – surgery – radiotherapy – chemotherapy – procarbazine-lomustine-vincristine – temozolomide – 1p/19q

Sources

1. Ba uman GS, Ino Y, Ueki K, Zlatescu MC, Fischer BJ, Macdonald DR et al. Allelic loss of chromosome 1p and radi otherapy plus chemotherapy in pati ens with oligodendrogli omas. Int J Radi at Oncol Bi ol Phys 2000; 48(3): 825– 830.

2. Ho ang- Xu an K, Capelle L, Kujas M, Taillibert S, Duffa u H, Leje une J et al. Temozolomide as initi al tre atment for adults with low- grade oligodendrogli omas or oligo astrocytomas and correlati on with chromosome 1p deleti ons. J Clin Oncol 2004; 22(15): 3133– 3138.

3. Chinot OL, Honore S, Dufo ur H, Barri e M, Figarella- Branger D, Muracci ole X et al. Safety and efficacy of Temozolomide in pati ens with recurrent anaplastic oligodendrogli omas after standard radi otherapy and chemotherapy. J Clin Oncol 2001; 19(9): 2449– 2455.

4. Chowdhary S, Chamberlain MC. Oligodendrogli al tumors. Expert Rev Ne urother 2006; 6(4): 519– 532.

5. Burger PC. What is an oligodendrogli oma? Brain Pathol 2002; 12(2): 257– 259.

6. Fortin D, Cairncross G, Hammond RR. Oligodendrogli oma: an appraisal of recent data pertaining to di agnosis and tre atment. Ne urosurgery 1999; 45(6): 1279– 1291.

7. Da umas- Duport C, Tucker ML, Kolles H, Cervera P, Be uvon F, Varlet P et al. Oligodendrogli omas. Part II: A new grading system based on morphological and imaging criteri a. J Ne uro oncol 1997; 34(1): 61– 78.

8. Stupp R, Hegi ME, van den Bent MJ, Mason WP, Keller M, Mirimanoff RO et al. Changing paradigms – an update on the multidisciplinary management of malignant gli oma. Oncologist 2006; 11(2): 165– 180.

9. van den Bent MJ, Carpenti er AF, Brandes AA, Sanson M, Tapho orn MJB, Bernsen HJJA et al. Adjuvant procarbazine, lomustine, and vincristine improves progressi on‑free survival but not overall survival in newly- di agnosed anaplastic oligodendrogli omas and oligo astrocytomas: a randomized Europe an Organisati on for Rese arch and Tre atment of Cancer phase III tri al. J Clin Oncol 2006; 24(18): 2715– 2722.

10. Cairncross G, Seiferheld W, Shaw E, Jenkins R, Scheitha uer B, Brachman D et al. An intergro up randomized controlled clinical tri al (RCT) of chemotherapy plus radi ati on (RT) versus RT alone for pure and mixed anaplastic oligodendrogli omas: initi al report of RTOG 94– 02. J Clin Oncol 2004; 23 (Suppl): 1500.

11. Cairncross G, Berkey B, Shaw E, Jenkins R, Scheitha uer B, Brachman D et al. Phase III tri al of chemotherapy plus radi otherapy compared with radi otherapy alone for pure and mixed anaplastic oligodednrogli oma: Intergro up Radi ati on Therapy Oncology Gro up Tri al 9402. J Clin Oncol 2006; 24(18): 2689– 2690.

12. Kozler P et al (eds). Intrakrani ální nádory. Praha: Galén 2007: 70– 84.

13. Kramář F, Zemanová Z, Michalová K, Babická L, Ransdorfová Š, Kozler P et al. Patogeneze mozkových gli omů, II. Část: Patogeneze oligodendrogli omů a gli omů v rámci dědičných onemocnění. Cesk Slov Ne urol N 2006; 69/ 102(6): 419– 425.

14. Jeon YK, Park K, Park CK, Paek SH, Jung HW, Park SH. Chromosome 1p and 19q and p 53 and p 16 expressi on patterns as prognostic indicators of oligodendrogli al tumors: a clinicopathological study using fluorescence in situ hybridizati on. Ne uropathology 2007; 27(1): 10– 20.

15. Je uken JW, Sprenger SH, Boerman RH, von Deimling A, Teepen HL, van Overbeeke JJ et al. Subtyping of oligo- astrocytic tumo urs by comparative genomic hybridizati on. J Pathol 2001; 194(1): 81– 87.

16. Dehghani F, Schachenmayr W, La un A. Prognostic implicati on of histopathological, immunohistochemical and clinical fe atures of oligodendrogli omas: a study of 89 cases. Acta Ne uropathol 1998; 95(5): 493– 504.

17. Shaw E, Arusell R, Scheitha uer B, O‘Fallon J, O‘Neill B, Dinapoli R et al. Prospective randomized tri al of low- versus high‑dose radi ati on therapy in adults with supratentori al low- grade gli oma: initi al report of a North Central Cancer Tre atment Gro up/ Radi ati on Therapy Oncology Gro up/ Eastern Co operative Oncology Gro up study. J Clin Oncol 2002; 20(9): 2267– 2276.

18. Karim AB, Maat B, Hatlevoll R, Menten J, Rutten EH, Thomas DG et al. A randomized tri al on dose‑response in radi ati on therapy of low- grade cerebral gli oma: Europe an Organizati on for Rese arch and Tre atment of Cancer (EORTC) study 22844. Int J Radi at Oncol Bi ol Phys 1996; 36(3): 549– 556.

19. Karim AB, Cornu P, Bleehan N, Afra D, de Witte O, Schra ub S et al. Immedi ate postoperative radi otherapy in low- grade gli oma improves progressi on‑free, but not overall survival: Preliminary results of an EORTC/ MRC randomized phase III study. Proc Am Soc Clin Oncol 1998; 17: 400.

20. Olson JD, Ri edel E, DeAngelis LM. Long term o utcome of low grade oligodendrogli oma and mixed gli oma. Ne urology 2000; 54(7): 1442– 1448.

21. Stege EM, Kros JM, de Bruin HG, Enting RH, van He uvel I, Lo o ijenga LHJ et al. Successful tre atment of low- grade oligodendrogli al tumors with chemotherapy regimen of Procarbazine, Lomustine, and Vincristine. Cancer 2005; 103(4): 802– 809.

22. Cairncross JG, Macdonald DR. Successful chemotherapy for recurrent malignant oligodendrogli oma. Ann Ne urol 1988; 23(4): 360– 364.

23. van den Bent MJ, Tapho orn MJ, Brandes AA, Menten J, Stupp R, Frenay O et al. Phase II study of first‑line chemotherapy with Temozolomide in recurrent oligodendrogli al tumors: The Europe an Organizati on for Rese arch and Tre atment of Cancer Brain Tumor Gro up Study 26971. J Clin Oncol 2003; 21(13): 2525– 2528.

24. Jaeckle KA, Ballman KV, Rao RD, Jenkins RB, Buckner JC. Current strategi es in tre atment of oligodendrogli oma: evoluti on of molecular signatures of response. J Clin Oncol 2006; 24(7): 1246– 1252.

25. van den Bent MJ, Chinot O, Bo ogerd W, Bravo Marques J, Tapho orn MJB et al. Second‑line chemotherapy with Temozolomide in recurrent oligodendrogli oma after PCV (Procarbasine, Lomustine an Vincristine) chemotherapy: EORTC Brain Tumor Gro up phase II study 26972. Ann Oncol 2003; 14(4): 599– 602.

26. van den Bent MJ, Keime- Guibert F, Brandes AA, Tapho orn MJB, Kros JM, Eskens FA et al. Temozolomide chemotherapy in recurrent oligodendrogli oma. Ne urology 2001; 57(2): 340– 342.

27. Tri ebels VH, Tapho orn MJ, Brandes AA, Menten J, Frenay M, Tosoni A et al. Salvage PCV chemotherapy for temozolomide‑resistant oligodendrogli omas. Ne urology 2004; 63(5): 904– 906.

28. Scopece L, Franceschi E, Cavallo G, Pai oli A, Pai oli G, Conforti R et al. Carboplatin and etoposide (CE) chemotherapy in pati ents with recurrent or progressive oligodendrogli al tumors. J Ne uro oncol 2006; 79(3): 299– 305.

29. Tali ansky- Aronov A, Bokstein F, Lavon I,Si egal T. Temozolomide tre atment for newly di agnosed anaplastic oligodendrogli omas: a clinical efficacy tri al. J Ne uro oncol 2006; 79(2): 153– 157.

30. Ko uwenhoven MC, Kros JM, French PJ, Bi emond- ter Stege EM, Graveland WJ, Tapho orn MJ et al. 1p/ 19q loss within oligodendrogli oma is predictive for response to first line temozolomide but not to salvage tre atment. Eur J Cancer 2006; 42: 2499– 2503.

31. Buckner JC, Gesme D jr, O‘Fallon JR, Hammack JE, Stafford S, Brown PD et al. Phase II tri al of Procarbasine, Lomustine, and Vincristine as initi al therapy for pati ens with low- grade oligodendrogli oma or oligo astrocytoma: efficacy and associ ati ons with chromosomal abnormaliti es. J Clin Oncol 2003; 21(2): 251– 255.